Mutual of America Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Mutual of America Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-82,834	Closed	-$2.77M	–	1476
2026 Q1	$2.77M	Sell	82,834 -332	-0.4%	-$13K	0.03%	628
2025 Q4	$3.85M	Buy	83,166 +4,333	+5%	+$238K	0.04%	525
2025 Q3	$5.33M	Buy	78,833 +579	+0.7%	+$42.9K	0.06%	414
2025 Q2	$6.56M	Buy	78,254 +5,672	+8%	+$425K	0.07%	317
2025 Q1	$5.19M	Buy	+72,582	New	+$3.53M	0.06%	404

Mutual of America Capital Management's SLNO Position: Q2 2026 in Review

Mutual of America Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 82,834 shares — an estimated $2.77M sold.

Mutual of America Capital Management first reported a position in SLNO in Q1 2025 and held it in 5 quarters. The position peaked at $6.56M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Mutual of America Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Mutual of America Capital Management sold 82,834 Soleno Therapeutics shares in Q2 2026, an estimated $2.77M.
Mutual of America Capital Management first reported a position in Soleno Therapeutics in Q1 2025 and held it in 5 quarters.
Mutual of America Capital Management's Soleno Therapeutics position peaked at $6.56M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Mutual of America Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.